KBTBD13 Inhibitors
Inhibitors of KBTBD13 primarily target the ubiquitin-proteasome system and autophagy pathways, both of which are integral to protein degradation and turnover in cells. The ubiquitin-proteasome system is a pathway for degrading proteins that have been tagged with ubiquitin, a small regulatory protein. Inhibitors such as MG-132, Lactacystin, Bortezomib, and Thalidomide can disrupt this system, leading to altered protein degradation rates that may influence the function of KBTBD13. On the other hand, autophagy is a process that cells use to degrade and recycle cytoplasmic components. SMER3, Chloroquine, 3-MA, and NH4Cl are chemicals that can modulate this pathway, either by enhancing or inhibiting it. KBTBD13's function could be influenced by changes in autophagic processes due to the disruption caused by these compounds.
PYR-41 and MLN4924 (Pevonedistat) target the ubiquitination process more directly. PYR-41 is an inhibitor of the E1 ubiquitin-activating enzyme, while MLN4924 inhibits the NEDD8-activating enzyme. By impeding these enzymes, the ubiquitination of proteins that KBTBD13 may interact with or regulate could be altered. Lastly, Epoxomicin and Omuralide (a synonym for Lactacystin) are selective proteasome inhibitors that specifically target the degradation of misfolded proteins. Disruption of this process can lead to the accumulation of proteins that may normally be regulated by KBTBD13, indirectly affecting its role in the cell.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
A proteasome inhibitor that can increase the levels of ubiquitinated proteins, potentially affecting KBTBD13's role in protein degradation. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $165.00 $575.00 | 60 | |
A specific inhibitor of the proteasome that can alter protein turnover and may indirectly affect KBTBD13 function. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Targets the 26S proteasome, which could impact the degradation pathway associated with KBTBD13. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $109.00 $350.00 | 8 | |
Modulates the ubiquitin-proteasome system and might influence the degradation processes involving KBTBD13. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $280.00 | 1 | |
Inhibits the NEDD8-activating enzyme, potentially disrupting ubiquitination pathways where KBTBD13 may be implicated. | ||||||
Ubiquitin E1 Inhibitor, PYR-41 | 418805-02-4 | sc-358737 | 25 mg | $360.00 | 4 | |
An inhibitor of ubiquitin-activating enzyme E1, could impede ubiquitination processes involving KBTBD13. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
A known autophagy inhibitor that can alter the degradation of cytoplasmic components, potentially influencing KBTBD13's function. | ||||||
Autophagy Inhibitor, 3-MA | 5142-23-4 | sc-205596 sc-205596A | 50 mg 500 mg | $56.00 $256.00 | 113 | |
Short for 3-Methyladenine, this compound inhibits autophagy, which may indirectly affect KBTBD13's cellular role. | ||||||
Ammonium Chloride | 12125-02-9 | sc-202936 sc-202936A sc-202936B | 25 g 500 g 2.5 kg | $38.00 $54.00 $147.00 | 4 | |
Ammonium chloride, can raise lysosomal pH and inhibit lysosome-autophagosome fusion, potentially affecting KBTBD13. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $134.00 $215.00 $440.00 $496.00 | 19 | |
A selective proteasome inhibitor, can interfere with the degradation of misfolded proteins, which may be linked to KBTBD13. | ||||||